1 Stashenko, P., Nadler, L. M., Hardy, R., and Schlossman, S. F. (1980) Characterization of a human b lymphocyte-specific antigen. J. Immunol. 125, 1678-1685.

2 Andeson, K. C., Bates, M. P., Slaughenhoup, B. L., Pinkus, G. S., Schlossman, S. F., and Nadler, L. M. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63, 1424-1433.

3 Bubien, J. K., Zhou, L. J., Bell, P. D., Frizzell, R. A., and Tedder, T. F. (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B-lymphocytes. J. Cell Biol. 121, 1121-1132.

4 Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., and Bonavida, B. (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12, 177-186.

.5 Shan, D., Ledbetter, J. A., and Press, O. W. (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48, 673-683.

6 Hofmeister, J. K., Cooney, D., and Coggeshall, K. M. (2000) Clustered CD20 induced apoptosis: src-family of kinase, the proximal regulator of tyrosine phos-phorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26, 133-143.

7. McLaughlin, P. (2001) Rituximab: perspective on single agent experience, and future directions in combinational trials. Crit. Rev. Oncol. Hematol. 40, 3-16.

8 Schulz, H., Winkler, U., Staak, J. O., and Engert, A. (2000) The monoclonal antibodies Campath-1H and rituximab in the therapy of chronic lymphocytic leukemia. Onkologie 23, 526-532.

9 Czuczman, M. S., Fallon, A., and Mohr, A. (2002) Rituximab in combination with CHOP or fludarabine in low grade lymphoma. Semin. Oncol. 18, 3135-3143.

10 Maloney, D. G., Liles, T. M., and Czerwinski, D. K. (1994) Phase I clinical trials using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457-2466.

11 Piro, L. D., White, C. A., Grillo-Lopez, A. J., et al. (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10, 655-661.

12 Coiffer, B., Haioun, C., and Ketterer, N. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multi-center phase II study. Blood 92, 1927-1932.

13 Davis, T. A., Czerwinski, D. K., and Levy, R. (1999) Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5, 611-615.

14 Flynn, J. M. and Byrd, J. C. (2000) Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol. 12, 574-581.

15 van Der Velden, V. H., te Marvelde, J. G., and Hoogeveen, P. G. et al. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97, 3197-3204.

Was this article helpful?

+1 0

Post a comment